Iron Deficiency Calculator

Q: What is the Ganzoni formula for calculating iron deficit?

The Ganzoni formula is the traditional and most widely used method for calculating total body iron deficit in patients with iron deficiency anemia. The formula is: Iron deficit (mg) = Body weight (kg) x (Target Hb - Actual Hb) (g/dL) x 2.4 + Iron stores (mg). The factor 2.4 is derived from the product of blood volume as a proportion of body weight (0.07 or 7%), the iron content of hemoglobin (0.00

Q: What are the common intravenous iron formulations available?

Several intravenous iron formulations are available, each with different dosing schedules, administration rates, and safety profiles. Iron sucrose (Venofer) is administered in 200 mg doses over 15 minutes, requiring multiple sessions for full repletion. Ferric carboxymaltose (Injectafer) allows up to 750 mg per infusion in the US (1000 mg in Europe), often requiring only 1-2 sessions. Low-molecula

Q: When should intravenous iron be preferred over oral iron supplementation?

Intravenous iron is preferred over oral iron in several clinical scenarios where oral iron is insufficient, poorly tolerated, or clinically inappropriate. These include intolerance or non-compliance with oral iron (gastrointestinal side effects affect 30-50% of patients), malabsorption conditions such as celiac disease, inflammatory bowel disease, or post-bariatric surgery, chronic kidney disease

Q: What laboratory tests confirm iron deficiency anemia?

The diagnosis of iron deficiency anemia requires a combination of laboratory tests that demonstrate both anemia and depleted iron stores. The complete blood count shows low hemoglobin and hematocrit, with microcytic (low MCV) and hypochromic (low MCH/MCHC) red blood cells. The red cell distribution width (RDW) is typically elevated, reflecting anisocytosis. Serum ferritin is the most specific test

Q: What are the potential side effects and risks of intravenous iron?

Intravenous iron is generally safe but carries potential risks that clinicians must consider. Minor infusion reactions including flushing, urticaria, myalgias, chest tightness, and back pain occur in approximately 1-3% of infusions and usually respond to slowing the infusion rate. Serious anaphylactic or anaphylactoid reactions are rare, occurring in approximately 0.1% of modern formulations (sign

Q: How should iron replacement be monitored after administration?

Monitoring after iron replacement therapy requires understanding the timeline of laboratory changes and appropriate test selection. Reticulocyte count typically increases within 5-7 days of adequate iron replacement, with peak reticulocytosis at 7-10 days. Hemoglobin begins rising within 2 weeks and should increase by approximately 1 g/dL every 2-3 weeks. Ferritin levels should be checked no soone

Calculate iron deficit and replacement dose from hemoglobin, weight, and target levels. Enter values for instant results with step-by-step formulas.

Share this calculator

X Facebook LinkedIn

Formula

Iron deficit (mg) = Weight(kg) x (Target Hb - Actual Hb)(g/dL) x 2.4 + Iron stores(mg)

The Ganzoni formula calculates total iron deficit by multiplying body weight by the hemoglobin deficit and a conversion factor of 2.4 (which accounts for blood volume and iron content of hemoglobin), then adding iron stores (typically 500 mg for adults >35 kg). The simplified approach uses fixed doses based on weight and hemoglobin categories.

Worked Examples

Example 1: Iron Deficit Calculation Using Ganzoni Formula

Problem: A 60 kg woman with iron deficiency anemia has a hemoglobin of 7.5 g/dL. Target hemoglobin is 12 g/dL. Calculate the total iron deficit using the Ganzoni formula with standard iron stores of 500 mg.

Solution: Ganzoni formula: Iron deficit = Weight x (Target Hb - Actual Hb) x 2.4 + Iron stores\nIron deficit = 60 kg x (12 - 7.5) g/dL x 2.4 + 500 mg\nIron for Hb correction = 60 x 4.5 x 2.4 = 648 mg\nIron for stores = 500 mg\nTotal iron deficit = 648 + 500 = 1,148 mg\nIron sucrose sessions (200 mg each): 6 sessions\nFerric carboxymaltose sessions (750 mg each): 2 sessions

Result: Total iron deficit: 1,148 mg - Requires 6 iron sucrose infusions or 2 ferric carboxymaltose infusions

Example 2: Simplified Dosing for CKD Patient

Problem: An 85 kg man with chronic kidney disease has hemoglobin of 9.2 g/dL and documented iron deficiency. Determine the appropriate iron replacement dose using the simplified approach.

Solution: Simplified dosing criteria:\nWeight: 85 kg (>=70 kg category)\nHemoglobin: 9.2 g/dL (<10 g/dL category)\nSimplified dose: 1,500 mg total\nFerric carboxymaltose: 2 sessions of 750 mg\nFerumoxytol: 3 sessions of 510 mg (1,530 mg total)\nIron dextran: 1 total dose infusion

Result: Simplified dose: 1,500 mg - Administer as 2 ferric carboxymaltose infusions or single iron dextran TDI

Frequently Asked Questions

What is the Ganzoni formula for calculating iron deficit?

The Ganzoni formula is the traditional and most widely used method for calculating total body iron deficit in patients with iron deficiency anemia. The formula is: Iron deficit (mg) = Body weight (kg) x (Target Hb - Actual Hb) (g/dL) x 2.4 + Iron stores (mg). The factor 2.4 is derived from the product of blood volume as a proportion of body weight (0.07 or 7%), the iron content of hemoglobin (0.0034 or 3.4 mg iron per gram of hemoglobin), and a unit conversion factor (1000). The iron stores component typically uses 500 mg for adults weighing more than 35 kg. This formula provides an individualized estimate that accounts for both the hemoglobin deficit and the need to replenish depleted iron stores.

What are the common intravenous iron formulations available?

Several intravenous iron formulations are available, each with different dosing schedules, administration rates, and safety profiles. Iron sucrose (Venofer) is administered in 200 mg doses over 15 minutes, requiring multiple sessions for full repletion. Ferric carboxymaltose (Injectafer) allows up to 750 mg per infusion in the US (1000 mg in Europe), often requiring only 1-2 sessions. Low-molecular-weight iron dextran (INFeD, CosmoFer) can deliver the total calculated dose in a single infusion over several hours. Ferumoxytol (Feraheme) is given as 510 mg infusions over 15 minutes, typically requiring 2-3 sessions. Ferric derisomaltose (Monoferric) can deliver up to 20 mg/kg in a single infusion. The choice depends on institutional availability, cost, patient convenience, and safety considerations.

When should intravenous iron be preferred over oral iron supplementation?

Intravenous iron is preferred over oral iron in several clinical scenarios where oral iron is insufficient, poorly tolerated, or clinically inappropriate. These include intolerance or non-compliance with oral iron (gastrointestinal side effects affect 30-50% of patients), malabsorption conditions such as celiac disease, inflammatory bowel disease, or post-bariatric surgery, chronic kidney disease especially in patients on dialysis, ongoing blood loss exceeding the absorption capacity of oral iron, severe iron deficiency anemia requiring rapid correction (hemoglobin below 7 g/dL), the second and third trimesters of pregnancy with significant anemia, and patients requiring erythropoiesis-stimulating agents who need adequate iron to support red blood cell production. IV iron achieves target hemoglobin levels faster than oral supplementation.

What laboratory tests confirm iron deficiency anemia?

The diagnosis of iron deficiency anemia requires a combination of laboratory tests that demonstrate both anemia and depleted iron stores. The complete blood count shows low hemoglobin and hematocrit, with microcytic (low MCV) and hypochromic (low MCH/MCHC) red blood cells. The red cell distribution width (RDW) is typically elevated, reflecting anisocytosis. Serum ferritin is the most specific test for iron stores, with levels below 30 ng/mL confirming iron deficiency (below 100 ng/mL in chronic kidney disease or inflammation). Serum iron is decreased while total iron-binding capacity (TIBC) is increased, resulting in a low transferrin saturation (below 20%). Soluble transferrin receptor levels are elevated. The reticulocyte hemoglobin content (CHr) below 28 pg is an early marker. The peripheral smear may show target cells, elliptocytes, and pencil cells.

What are the potential side effects and risks of intravenous iron?

Intravenous iron is generally safe but carries potential risks that clinicians must consider. Minor infusion reactions including flushing, urticaria, myalgias, chest tightness, and back pain occur in approximately 1-3% of infusions and usually respond to slowing the infusion rate. Serious anaphylactic or anaphylactoid reactions are rare, occurring in approximately 0.1% of modern formulations (significantly less than older high-molecular-weight iron dextran). Hypophosphatemia is a recently recognized complication, particularly with ferric carboxymaltose, which can cause phosphate wasting and rarely symptomatic hypophosphatemia. Extravasation can cause tissue staining. Long-term risks of iron overload exist if dosing exceeds actual deficit. Fishbane reactions (complement-activated pseudo-allergic reactions) can mimic true anaphylaxis but are generally self-limiting.

How should iron replacement be monitored after administration?

Monitoring after iron replacement therapy requires understanding the timeline of laboratory changes and appropriate test selection. Reticulocyte count typically increases within 5-7 days of adequate iron replacement, with peak reticulocytosis at 7-10 days. Hemoglobin begins rising within 2 weeks and should increase by approximately 1 g/dL every 2-3 weeks. Ferritin levels should be checked no sooner than 8-12 weeks after the last IV iron dose because ferritin is transiently elevated immediately after infusion and during acute phase responses. A target ferritin above 100 ng/mL and transferrin saturation above 20% indicates adequate repletion. If hemoglobin fails to respond as expected, clinicians should investigate ongoing blood loss, malabsorption, concurrent deficiencies (B12, folate), chronic disease, or incorrect diagnosis.